We have investigated the protective effects of ITH91/IQM157, a hybrid of melatonin and N, N-dibenzyl(N-methyl)amine, in an in vitro model of AD-like pathology that combines amyloid beta (A) and tau hyperphosphorylation induced by okadaic acid (OA), in the human neuroblastoma cell line SH-SY5Y. Combination of sub-toxic concentrations of A and OA caused a significant toxicity of 40% cell death, which mainly was apoptotic; this effect was accompanied by retraction of the cell´s prolongations and accumulation of thioflavin-S stained protein aggregates. In this toxicity model, ITH91/IQM157 (1-1000 nM) reduced cell death measured as MTT reduction; at 100 nM, it prevented apoptosis, retraction of prolongations and βA aggregates. The protective actions of ITH91/IQM157 were blocked by mecamylamine, luzindol, chelerythrine, PD98059, LY294002 and SnPP. We show that the combination of melatonin with a fragment endowed with AChE inhibition in a unique chemical structure, ITH91/IQM157, can reduce neuronal cell death induced by Aand OA by a signaling pathway that implicates both nicotinic and melatonin receptors, PKC, Akt, ERK1/2 and induction of hemoxygenase-1.
INTRODUCTION
Alzheimer´s disease (AD) is the most common form of dementia. There are about 27 millions of patients in the world and this figure could increase to 107 million by the year 2050 if no treatment is found to delay the onset or the progression of the disease (1) . Therefore, the development of an effective treatment is a social, economic and political global priority.
From a histopathological point of view, AD is characterized by two protein alterations, namely tau hyperphosphorylation and excessive amyloid beta (Aβ) deposition, both related to the neuronal degeneration (2-4.) This neurodegenerative process affects the cholinergic system, among others. Therefore, acetylcholinesterase inhibitors are the main drugs used today to treat these patients. For later stages of the disease, inhibition of NMDA receptors with memantine is also used. A meta-analysis for commercially available acetylcholinesterase inhibitors (AChEI) and memantine in combination for the treatment of patients with AD revealed only a modest trend favoring active treatment over placebo (5) . Therefore, the search for new compounds to treat this disease is still mandatory.
The use of multitarget compounds is emerging as an interesting strategy to treat different pathologies. These compounds combine, in a single molecule, complementary activities over different pathways of the pathophysiological cascade of AD. More specifically, our group has become interested in compounds that combine fragments derived from an inhibitor of acetylcholinesterase (AChEI) and melatonin for the following reasons: (i) AChEI are the drugs mainly used in clinic to treat AD patients; their mechanism of action is based on the improvement of cholinergic neurotransmission, (ii) the levels of the neurohormone melatonin, endowed with antioxidant properties (6) , are gradually reduced with age. In the cerebral spinal fluid (CSF), melatonin levels can be reduced by 50% when compared to young subjects; this reduction is even greater in AD patients (below 20%) (7) (8) (9) . It is also worth mentioning that hippocampal CA1 and CA3 pyramidal neuronal loss can be reproduced in rats by removing their pineal gland, while replacement of melatonin in the drinking water recovers such loss (10) . Furthermore, melatonin has shown neuroprotective effect in several AD models (8, (11) (12) (13) (14) , and it has also shown beneficial effects in a double blind study on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia (15) . For all these reasons, melatonin could be beneficial in AD (16) and, (iii) previous results from our group have shown that the combination of subeffective concentrations of galantamine and melatonin offer a significant neuroprotective effect in SH-SY5Y cells against mitochondrial intoxication with rotenone and oligomycin A (17) . With these ideas in mind, we synthesized several melatonin -N,N-dibenzyl(N-methyl)amine hybrids (18) ; the idea of keeping the AChEI activity, even if modest, was based on the fact that this target remains clinically valid for the majority of drugs (donepezil, rivastigmine and galantamine) used today in AD patients. In this study we have focused on ITH91/IQM157 (Fig 1) that shares chemical features of melatonin and the AChEI AP2238, has low toxicity, is capable of crossing the blood brain barrier in a predictive model and has an interesting pharmacological profile with potential for the treatment of AD. It inhibits human AChE (IC 50 = 4.1 µM), displaces propidium from the peripheral anionic site of AChE (25% at 1.0 µM), presents antioxidant properties (ORAC = 1.5 trolox equiv.) and protects neural cells against mitochondrial free radicals (26% at 1.0 µM) (18) . is also proposed that these alterations are not independent, but are interrelated (19, 20) .
Although there are several in vivo models that combine A pathology with tau pathology, such as the double transgenic mice APPswe/TauVLW (21) or the triple transgenic PS1M146V, APPswe, and TauP301L (22) , virtually no in vitro models combine these two alterations. Therefore we have implemented an in vitro model that combines beta and tau pathology by combining A [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] and okadaic acid in the human neuroblastoma cell line SH-SY5Y. We have used this model to evaluate the potential neuroprotective effects of the melatonin -N,N-dibenzyl(N-methyl)amine hybrid ITH91/IQM157.
RESULTS AND DISCUSION
In order to set up the cytotoxicity model, we first performed concentrationresponse curves with Aand okadaic acid in the human neuroblastoma cell line SHSY5YOkadaic acid (OA), a phosphatase inhibitor that causes hyperphospholylation of tau protein (23) , was more effective to induce cell death than A; in fact, maximum cell death achieved with A was near 40 % (10 M  Fig ) while with OA, maximum cell death reach over 80 % (30 nM OA, Fig 2B) . Interestingly, when sub-effective concentrations of both stimuli (1 M of A and 3 nM of OA) were combined, we observed a significantly higher cytotoxic effect compared to each toxin alone (Fig. 2C) .
This result was corroborated in a primary neuronal culture, in which a similar toxicity was observed (Supplemental data1). Therefore, this result validates the use of a neuronal cell line instead of primary neuronal cultures which "Replaces" the use of animals. When we analyzed the apoptotic and necrotic populations in SH-SY5Y cells exposed to A (1 M) in combination with OA (3 nM) -from now on A /OA-, we found that cell death was mainly apoptotic (Fig. 4B) . These results are consistent with those described in animal models of AD where mutations associated with overexpression of Aprotein and mutations associated with hyperphosphorylation of tau, are combined (22, 24) ; these animals show greater pathology and functional alterations in a more precocious way compared to mono-transgenics. Besides the effects on cell death, subtoxic concentrations of A/OA caused neurite retraction (Fig. 5B) , an effect related to tau hyperphosphorylation, which causes microtubule destabilization, cytoarchitecture loss and, consequently, neurodegeneration (3, 23) . This degeneration and cell death is also reflected in the emergence of more pyknotic nuclei in cells treated with A/OA. We also found aggregates of thioflavin S staining as an indication of Aaggregation ( To test the hypothesis that a significant neuroprotective effect could be achieved with the combination of sub-effective concentrations of melatonin and an AChEI, we used 1 nM of melatonin plus 10 nM of donepezil in the A/OA toxicity model; indeed the drug combination afforded significant protection (57% protection) compared to the drugs alone (Fig. 3C) .
Next, we evaluated the potential neuroprotective effect of the melatonin -N,Ndibenzyl(N-methyl)amine hybrid ITH91/IQM157. Compared to melatonin or the acetylcholinestarase inhibitor donepezil, the neuroprotective actions found with ITH91/IQM157 were achieved at lower concentrations; at 1 nM, ITH91/IQM157 already offered maximum protection (Fig. 4A) . This hybrid improved the neuroprotective activity in comparison to the combination strategy of subeffective concentrations of melatonin (1 nM) and donepezil (10 nM); protection was 75 % with 1 nM ITH91/IQM157 vs 57% with the combination strategy (Fig. 3C) . This finding agrees with our previous observation that combination of subeffective concentrations of melatonin and the AChEI galantamine offers significant neuroprotection (17) . Concerning the neuroprotective mechanism of action of ITH91/IQM157, both melatonin and nicotinic receptors seem to be implicated since both luzindole (a melatonin receptor antagonist) and mecamylamine (a nicotinic receptor antagonist) significantly reduced its protective effect (Fig. 6A) . The involvement of nAChRs has also been implicated in the protective effects of other AChE inhibitors like galantamine and donepezil (25) (26) (27) . The neuroprotective effect of ITH91/IQM157 was accompanied by the recovery of the cytoarchitecture and a reduction of thioflavin-S aggregates ( Fig.   5C and F) . The reduction of protein aggregates can be related to actions of the melatonin substructure, since it is reported that melatonin can directly interact with
Aand prevent its aggregation (28, 29) and it can also interfere with APP processing (30) (31) (32) . Furthermore, we previously reported that compound ITH91/IQM157 displaces propidium iodide from the peripheral acetylcholinesterase site, which is known to participate in A aggregation (33) . Interaction with MT 2 receptors can stimulate phospholipase C and activate protein kinase C (PKC) via diacylglycerol, which in turn phosphorylates and inactivates GSK-3β, whose participation in APP synthesis (34, 35) and tau hyperphosphorylation are well documented; this could be an additional mechanism for compound ITH91/IQM157. In fact, the protective mechanism of ITH91/IQM157 was partially inhibited by the PKC inhibitor chelerythrine (Fig. 6B) . Fig. 7A and 7B ) and its protective actions were prevented in the presence of inhibitors of these kinases (Fig. 6B) . Akt can phosphorylate GSK-3 at position Ser-9, inactivating it (38-40) and can improve neuronal survival by: (i) contributing to reduction of  and tau pathology as mentioned above and/or (ii) promoting the nuclear translocation of Nrf2 (nuclear factor E2-related factor 2) to increase the cell´s defense mechanisms (41). Fig 7C) , and, most interesting, its protective actions were prevented when an inhibitor of this antioxidant enzyme (SnPP) was added to the cells (Fig. 6B) . These results indicate that part of its neuroprotective actions can be attributed to induction of HO-1 as already described for other neuroprotective drugs that interact with melatonin or nicotinic receptors (36, 42, 43) . 
MATERIALS AND METHODS

Materials
Amyloid beta (A [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] 
Culture of the human neuroblastoma cell line SH-SY5Y
SH-SY5Y cells were maintained in culture medium containing 10 % inactivated fetal bovine serum, 15 nonessential aminoacids, 1 mM sodium pyruvate (Invitrogen, Madrid, Spain), F12 nutrient medium (Ham12), MEM medium (Eagle's minimum essential medium) (Sigma Aldrich, Madrid, Spain), NaHCO 3 , 100 U/ml penicillin and 100 µg/ml streptomycin (Invitrogen, Madrid, Spain) in H 2 0 miliQ. Cells were grown initially in a flask and sub-cultured in 48-well plates at a density of 1x10 5 cells/well.
Cells were maintained in an incubator in a humid atmosphere at 37°C with 5 % CO 2 ;
they were used between 4-12 passages. 
Measurement of cell viability using the MTT method
Double staining of SH-SY5Y cells with phalloidin and Hoechst
We used phalloidin-rhodamin staining to detect the cellular cytoskeleton in our experimental conditions. Hoechst staining was concomitantly used to detect the nuclei.
At the end of the experiment, SH-SY5Y cells were washed 3 times with PBS (NaCl 9 g/L, 10 mM NaH 2 PO 4 , 10 mM K 2 HPO 4 ) and fixed with 2 % paraformaldehyde 
Statistical analysis
Data are presented as means ± SEM. Differences between groups were determined by applying a one-way ANOVA followed by a Newman-Keuls post hoc analysis. The level of statistical significance was taken at p < 0.05.
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